Merck & Co., Inc: Nausea trials

The registry lists 11 Nausea studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 2 4Phase 3 1Phase 4 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)CompletedNCT01732458Phase 2Results posted
• A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)CompletedNCT01636947Phase 4Results posted
• Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)TerminatedNCT01405924Phase 2Results posted
• Re-examination Study of EMEND (Aprepitant) (MK-0869-184)CompletedNCT01074255Results posted
• Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)CompletedNCT00687011Phase 4
• Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)CompletedNCT00684463Phase 4
• A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)CompletedNCT00539721Phase 2
• A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)CompletedNCT00394966Phase 2
• Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)CompletedNCT00092196Phase 3
• An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)CompletedNCT00092183Phase 4
• Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)CompletedNCT00090207Phase 4